Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research.

Ruigrok EAM, van Weerden WM, Nonnekens J, de Jong M.

Pharmaceutics. 2019 Oct 29;11(11). pii: E560. doi: 10.3390/pharmaceutics11110560. Review.

2.

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.

Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

PMID:
30843003
3.

Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.

Chatalic KL, Heskamp S, Konijnenberg M, Molkenboer-Kuenen JD, Franssen GM, Clahsen-van Groningen MC, Schottelius M, Wester HJ, van Weerden WM, Boerman OC, de Jong M.

Theranostics. 2016 Apr 12;6(6):849-61. doi: 10.7150/thno.14744. eCollection 2016.

4.

Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.

Arsenault F, Beauregard JM, Pouliot F.

Curr Opin Support Palliat Care. 2018 Sep;12(3):359-365. doi: 10.1097/SPC.0000000000000357. Review.

PMID:
29939893
5.

A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.

Chatalic KL, Veldhoven-Zweistra J, Bolkestein M, Hoeben S, Koning GA, Boerman OC, de Jong M, van Weerden WM.

J Nucl Med. 2015 Jul;56(7):1094-9. doi: 10.2967/jnumed.115.156729. Epub 2015 May 14.

6.

Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals.

Diao W, Cai H, Chen L, Jin X, Liao X, Jia Z.

Curr Top Med Chem. 2019;19(1):33-56. doi: 10.2174/1568026619666190201100739. Review.

PMID:
30706785
7.

Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.

Farolfi A, Fendler W, Iravani A, Haberkorn U, Hicks R, Herrmann K, Walz J, Fanti S.

Eur Urol Oncol. 2019 Mar;2(2):152-162. doi: 10.1016/j.euo.2019.01.001. Epub 2019 Jan 31. Review.

PMID:
31017091
8.

PSMA PET and Radionuclide Therapy in Prostate Cancer.

Bouchelouche K, Turkbey B, Choyke PL.

Semin Nucl Med. 2016 Nov;46(6):522-535. doi: 10.1053/j.semnuclmed.2016.07.006. Epub 2016 Sep 3. Review.

9.

PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status.

Lütje S, Heskamp S, Cornelissen AS, Poeppel TD, van den Broek SA, Rosenbaum-Krumme S, Bockisch A, Gotthardt M, Rijpkema M, Boerman OC.

Theranostics. 2015 Oct 18;5(12):1388-401. doi: 10.7150/thno.13348. eCollection 2015. Review.

10.

Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy.

Meller B, Bremmer F, Sahlmann CO, Hijazi S, Bouter C, Trojan L, Meller J, Thelen P.

EJNMMI Res. 2015 Dec;5(1):66. doi: 10.1186/s13550-015-0145-8. Epub 2015 Nov 17.

11.

68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer.

Malaspina S, De Giorgi U, Kemppainen J, Del Sole A, Paganelli G.

Radiol Med. 2018 Dec;123(12):952-965. doi: 10.1007/s11547-018-0929-9. Epub 2018 Aug 16. Review.

PMID:
30116970
12.

Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals.

Wüstemann T, Bauder-Wüst U, Schäfer M, Eder M, Benesova M, Leotta K, Kratochwil C, Haberkorn U, Kopka K, Mier W.

Theranostics. 2016 Apr 28;6(8):1085-95. doi: 10.7150/thno.13448. eCollection 2016.

13.

PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.

Rowe SP, Gorin MA, Allaf ME, Pienta KJ, Tran PT, Pomper MG, Ross AE, Cho SY.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):223-30. doi: 10.1038/pcan.2016.13. Epub 2016 May 3. Review.

14.

Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer.

Kelly JM, Amor-Coarasa A, Nikolopoulou A, Wüstemann T, Barelli P, Kim D, Williams C Jr, Zheng X, Bi C, Hu B, Warren JD, Hage DS, DiMagno SG, Babich JW.

J Nucl Med. 2017 Sep;58(9):1442-1449. doi: 10.2967/jnumed.116.188722. Epub 2017 Apr 27.

15.

Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.

Chakravarty R, Siamof CM, Dash A, Cai W.

Am J Nucl Med Mol Imaging. 2018 Aug 20;8(4):247-267. eCollection 2018. Review.

16.

Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.

Schottelius M, Wurzer A, Wissmiller K, Beck R, Koch M, Gorpas D, Notni J, Buckle T, van Oosterom MN, Steiger K, Ntziachristos V, Schwaiger M, van Leeuwen FWB, Wester HJ.

J Nucl Med. 2019 Jan;60(1):71-78. doi: 10.2967/jnumed.118.212720. Epub 2018 Sep 20.

17.

The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.

Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, Eisenhut M, Kübler W, Holland-Letz T, Giesel FL, Mier W, Kopka K, Haberkorn U.

J Nucl Med. 2015 Nov;56(11):1697-705. doi: 10.2967/jnumed.115.161299. Epub 2015 Aug 20.

18.

New aspects of molecular imaging in prostate cancer.

Ceci F, Castellucci P, Cerci JJ, Fanti S.

Methods. 2017 Nov 1;130:36-41. doi: 10.1016/j.ymeth.2017.07.009. Epub 2017 Jul 13. Review.

PMID:
28711565
19.

Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.

Miyahira AK, Pienta KJ, Morris MJ, Bander NH, Baum RP, Fendler WP, Goeckeler W, Gorin MA, Hennekes H, Pomper MG, Sartor O, Tagawa ST, Williams S, Soule HR.

Prostate. 2018 Aug;78(11):775-789. doi: 10.1002/pros.23642. Epub 2018 May 1. Review.

PMID:
29717499
20.

PET/CT With 68Ga-PSMA in Prostate Cancer: Radiopharmaceutical Background and Clinical Implications.

Giovacchini G, Giovannini E, Riondato M, Ciarmiello A.

Curr Radiopharm. 2018;11(1):4-13. doi: 10.2174/1874471010666171101121803. Review.

PMID:
29090673

Supplemental Content

Support Center